Brief: ABVC Biopharma Provides ADHD Phase II Part 2 Clinical Study Update
23/09/2022 13:46
Sept 23 (Reuters) - ABVC Biopharma Inc ABVC.O :
* ABVC BIOPHARMA PROVIDES ADHD PHASE II PART 2 CLINICAL
STUDY
UPDATE AND ANNOUNCES UCSF INSTITUTIONAL REVIEW BOARD APPROVAL
* ABVC BIOPHARMA - SINCE RESULTS OF 1ST SUBJECT TREATED IN
TAIWAN
REPORTED ON MAY 10, 30 SUBJECTS ENROLLED IN STUDY FROM TOTAL OF
43 SUBJECTS SCREENED
* ABVC BIOPHARMA INC - 18 OF ENROLLED PARTICIPANTS HAVE
ALREADY
COMPLETED 8-WEEK TREATMENT IN ACCORDANCE WITH STUDY DESIGN
Source text for Eikon: ID:nGNXbnqdcn
Further company coverage: ABVC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ABVC Biopharma
See all newsBrief: ABVC Biopharma - Quarterly Period Ended September, 2025 Financial Statements Should Not Be Relied Upon
Brief: Abvc Biopharma Inc Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: ABVC Biopharma Concluded That Financial Statements For FY Ended Dec 31, 2023 Should No Longer Be Relied Upon Due To Errors In Financial Statements
Brief: ABVC Biopharma Inc On March 5, Leeds Chow Resigns As CFO Of Abvc Biopharma
Brief: ABVC Biopharma Secures $200,000 In First Cash Licensing Payment From Oncology Products Partner